- ABOUT US
- GENE EDITING
- Animal & Cell Models
- Animal Models
- Humanized Immune-Checkpoint Mice
- Humanized Cytokine Mice
- Humanized GPCR Mice
- Other Humanized Models
- Immunodeficient Mice (B-NDG background)
- Immunodeficient Mouse Models (Non B-NDG background)
- Reporter Models
- Cre Mouse/Rat Models
- DTR Models
- Other Tool Models
- Disease Mouse Models
- Drug Target Knockout Mouse Models
- Other Knockout Mouse Models
- Cell Lines
- Animal Models
- Efficacy & Toxicity Studies
- Inflammatory Disease Modeling
- Psoriasis Model
- Atopic Dermatitis Model
- Delayed type hypersensitivity model
- Acute Lung Injury & Inflammation Models
- Asthma Model
- Bleomycin-Induced Pulmonary Fibrosis Model
- Rheumatoid Arthritis Model
- Ovariectomy (OVX) induced Osteoporosis Model
- Osteoarthritis Model
- EAE Model
- LPS Mouse Model of Acute Inflammation
- Inflammatory Bowel Disease Model
- Systemic Lupus Erythematosus Model
- 5/6 Nephrectomy Chronic Kidney Disease Model
- Metabolic Disease Models
- NASH Mouse Models
- High-fat diet-induced obese (DIO) mouse model
- Type 2 Diabetes Mouse Model
- STZ Mouse Model
- Bile duct ligation-induced liver fibrosis Mouse Model
- TAA (Thioacetamide) -induced liver fibrosis Mouse Model
- Acetaminophen-induced Liver Injury Model
- Concanavalin A hepatitis model
- Atherosclerosis model
- In Vivo Pharmacology Services
- PK/PD Assays & In vitro Pharmacology Studies
- Efficacy & Toxicity Case Studies
- Inflammatory Disease Modeling
- RenMice™ Platforms
- Preclinical & Clinical Assets
- Antibody Hits Library
- Agonistic anti-CD40 IgG2 antibody YH003
- Anti-CTLA-4 IgG1 monoclonal antibody YH001
- Anti-OX40 IgG1 antibody YH002
- Agonistic anti-4-1BB IgG1 antibody YH004
- Anti-PD-1 x CD40 bispecific antibody YH008
- HER2 x TROP2 bispecific ADC YH012
- Antagonistic anti-CD40 fully human antibody YH015
- News & Resources
- Investors
